The effects of hGH and AOD9604 on fat metabolism may be mediated by an alteration in the expression of a lipolytic/antilipogenic gene. Theβ 3-AR is a major lipolytic receptor identified in rodent fat cells (18) that mediates its effects through G protein coupling to adenylate cyclase, generation of cAMP, and stimulation of PKA (19). This enzyme then phosphorylates proteins in the lipolytic cascade, including hormone-sensitive lipase (20). In BAT, the β3-AR stimulates uncoupling of the electron transport chain, enhancing the ability of mitochondria to generate heat in preference to ATP through the dissipation of the electron gradient (21). Mice that lack this receptor have lower rates of resting energy expenditure (0.0041 vs. 0.0047 kcal/min, P < 0.02) and lower rates of fat oxidation (0.00019 vs. 0.00030 g/min, P < 0.02) than control mice (data not shown).

The company which developed it, Metabolic Pharmaceuticals, did have a small early study done which showed a small amount of fat loss at 1 mg per day but not really any other dosing. Measured effect was less at higher doses. In total the company did at least six studies. According to the lead researcher of five of the studies, Dr Gary Wittert, results were uniformly negative.

Some athletes and bodybuilders help their body with the weight loss process using peptides like GHRP-2, a growth hormone releasing peptide. GHRP-2 has been shown to increase bone density and cellular repair, increase lean body mass, decrease body fat, and improve sleep. Combined with a reduced calorie diet and exercise program, GHRP-2 can help you achieve your weight loss and fitness goals faster.
Prof. Gary Wittert, Adelaide-based Principal Investigator on the study, said: “As the world’s first drug with a metabolic mechanism of action AOD9604 could occupy a unique position among the options available to doctors for the management of obesity. It is pleasing that the invention and its development from the laboratory bench has been an all–Australian effort.”
Also, as we age, our metabolic processes slow down, leading to less background energy consumption. Less exercise promoting muscular strength gets exchanged for walking and taking the stairs. This reduces muscle that burns fat and increases the metabolism again causing fat storage due to lack of activity. The result is obesity, which is now a pandemic.
Paracetamol/caffeine formulations have a long-established safety and efficacy profile over 25 years of use as an open-sale medicine in major markets around the world. The paracetamol/caffeine combination analgesic was registered as a schedule 2 product in Australia and has been marketed since 2010. Since that time no new significant issues or potential risks have been reported.
The acute effect of AOD9604 and BRL37344 (aβ 3-AR agonist) on energy expenditure and substrate oxidation rates in WT and KO mice was also assessed. KO animals had lower energy expenditure, lower fat oxidation, and increased glucose oxidation, compared with the WT controls (data not shown). Injection of WT mice with a single dose of BRL37344 or AOD9604 increased energy expenditure and fat oxidation and decreased glucose oxidation. In the KO animals, BRL37344 failed to elicit any response in these metabolic parameters, clearly demonstrating that its effects are mediated exclusively through the β3-AR. AOD9604 did elicit a response in the KO mice, increasing fat oxidation and energy expenditure, although the response was not as great as in WT mice, suggesting that β3-ARs are not responsible for the acute biological response of AOD9604 on lipid metabolism. This is consistent with our previous findings in which AOD9604 was shown not to bind to the β3-AR (11). The size and duration of the metabolic responses to AOD9604 in the β3-AR KO animals was different from that observed in the control wild-type mice. The response was more rapid, shorter in duration, and greater in peak response. This may be because the KO animals are more acutely sensitive to lipolytic agents, a compensation for the ablation of the major lipolytic receptor.
In summary, we found that weight loss in obese individuals undergoing gastric bypass surgery is associated with higher natriuretic peptide concentrations across a range of loading conditions. This observation is consistent with a higher “set point” of natriuretic peptide levels after weight loss. That these findings are accompanied by improvements in blood pressure, heart rate and echocardiographic diastolic function provides persuasive evidence that the increase in natriuretic peptides with weight loss is “primary” and not secondary to alterations in cardiac structure or function.
Since I drank my peptides in the morning with my coffee (around 9:30), I found myself full until lunchtime. I tend to take a later lunch, around 2:30, so I typically have a snack sometime mid-morning to tide me over. However, I found I didn’t need my morning snack after I had the collagen. It also helped to pair my collagen coffee with breakfast, especially if I ate something that wasn’t super high in protein such as avocado toast. The 9 grams of protein from the collagen kept me satisfied until my next meal.
Mod GRF 1-29 and CJC-1295 are still being researched. As such, they are not yet medically utilized or approved. Though some firm protocols for the use of these peptides have been developed, the dosage of the compound is not yet medically confirmed. In a study conducted by researchers on 21 to 61 year-old subjects, it was found that depending on the dose, the concentrations of the growth hormone increased to up to 10 times for at least 6 days. Also, the concentration of IGF-1 increased to up to 3 times for 9 to 11 days.
The biggest negative, and this is a big one, is that AOD9604 has undergone very rigorous scientific testing, and has been found to have no effect in humans (3). When AOD9604 was first developed, it showed significant promise as a weight loss treatment. A special strain of obese mice supplemented with the peptide showed a reduction in weight, increased fat oxidation, and raised plasma glycerol, which are indicators of lipolysis, or fat burning (5). Subsequent studies in obese mice and rats attempted to show that the peptide works to burn fat in the same way as human growth hormone, but found that this was not the case, meaning that the fact this peptide resembled hGH was meaningless. Scientists were unable to determine how this peptide was working in mice (6).
Also, as we age, our metabolic processes slow down, leading to less background energy consumption. Less exercise promoting muscular strength gets exchanged for walking and taking the stairs. This reduces muscle that burns fat and increases the metabolism again causing fat storage due to lack of activity. The result is obesity, which is now a pandemic.

Buy Peptides online from Australia’s most respected supplier of clinical grade peptides. Peptides Online produces only the highest quality peptide products. We are fully licensed and registered with our offices located in Australia. Specializing in the production of medically prescribed, pharmaceutical grade peptides, Peptide Online guarantees optimal purity and potency of their peptide supplements.

×